Influenza Infection

Infectious Diseases
6
Pipeline Programs
5
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 5 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

GC Biopharma
GC BiopharmaKorea - Yongin
1 program
1
Adjuvanted influenza APhase 31 trial
Active Trials
NCT01201902CompletedEst. Jul 2010
Ansun BioPharma
Ansun BioPharmaCA - San Diego
1 program
1
DAS181Phase 21 trial
Active Trials
NCT04298060Unknown280Est. Sep 2022
Takeda
TakedaTOKYO, Japan
1 program
1
TAK-850 0.5 mL injectionPhase 1/21 trial
Active Trials
NCT02367885Completed99Est. May 2015
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
2
A/Mallard/Ohio-99/MM4/1989 H10N7Phase 11 trial
VRC-FLUNPF099-00-VPPhase 11 trial
Active Trials
NCT05436444CompletedEst. Dec 2024
NCT03814720CompletedEst. Apr 2021
Novartis
NovartisBASEL, Switzerland
1 program
1
Subunit influenza vaccinePhase 1Vaccine1 trial
Active Trials
NCT00559975Completed60Est. May 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GC BiopharmaAdjuvanted influenza A
Ansun BioPharmaDAS181
TakedaTAK-850 0.5 mL injection
Allergy TherapeuticsA/Mallard/Ohio-99/MM4/1989 H10N7
Allergy TherapeuticsVRC-FLUNPF099-00-VP
NovartisSubunit influenza vaccine

Clinical Trials (6)

Total enrollment: 439 patients across 6 trials

NCT01201902GC BiopharmaAdjuvanted influenza A

A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine

Start: Oct 2009Est. completion: Jul 2010
Phase 3Completed

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)

Start: Jul 2020Est. completion: Sep 2022280 patients
Phase 2Unknown
NCT02367885TakedaTAK-850 0.5 mL injection

Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants

Start: Feb 2015Est. completion: May 201599 patients
Phase 1/2Completed
NCT05436444Allergy TherapeuticsA/Mallard/Ohio-99/MM4/1989 H10N7

Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model

Start: Oct 2023Est. completion: Dec 2024
Phase 1Completed

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

Start: Apr 2019Est. completion: Apr 2021
Phase 1Completed
NCT00559975NovartisSubunit influenza vaccine

Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

Start: Oct 2007Est. completion: May 200860 patients
Phase 1Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space